Clinical trials: Stage IIIC
Breast Cancer
Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, doxorubicin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00589238
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Centre, Singapore
Breast Cancer
Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00870415
- Testing
- quality-of-life assessment, therapeutic conventional surgery
- Where
- France
- Volunteers
- 263 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Melanoma
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin.
- Trial name
- NCT02143050
- Testing
- Dabrafenib, Trametinib, Metformin
- Where
- 2 sites in United States
- Sponsor
- University of Louisville
Breast Cancer
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00379509
- Testing
- lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer
M-Trap is an implantable medical device designed to capture disseminated tumor cells (DTCs). It is intended for use in advanced-stage ovarian cancer patients.
- Trial name
- NCT03085238
- Testing
- M-Trap
- Where
- 8 sites in Spain
- Volunteers
- 23 people
- Sponsor
- MTrap, Inc.
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby tissue or lymph nodes or other parts of the body…
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT02311933
- Testing
- Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 559 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)
The main objective of this study is to evaluate the clinical and biologic toxicity of cell therapy by adoptive transfer of TIL in combination with intra-tumoral injections of Ad-INFg.
- Trial name
- NCT01082887
- Testing
- TIL-Ad-INFg
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Nantes University Hospital
Lung Cancer, Non-Small Cell
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung…
- Trial name
- ZEAL-1L (NCT04475939)
- Testing
- Niraparib, Pembrolizumab
- Where
- 188 sites in United States, Argentina and 25 more
- Volunteers
- 666 people
- Sponsor
- GlaxoSmithKline
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and…
- Conditions
- Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT03281902
- Testing
- Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Colon Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which schedule of chemotherapy is most effective in treating colon cancer.
- Trial name
- NCT00046995
- Testing
- carboplatin, fluorouracil, leucovorin calcium
- Where
- 2 sites in Belgium
- Volunteers
- 800 people
- Sponsor
- Groupe Regional d'Etudes du Cancer Colorectal
Breast Cancer
Study of Tumor and Blood Samples From Women With Breast Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897728
- Testing
- laboratory biomarker analysis
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Institut Curie
Colorectal Cancer
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00686166
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- 130 sites in United States
- Volunteers
- 83 people
- Sponsor
- SWOG Cancer Research Network
Stage IA Skin Melanoma, Stage IB Skin Melanoma
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma
- Conditions
- Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
- Trial name
- NCT01460875
- Testing
- recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- William Carson
Metastatic Melanoma
Radiotherapy & Combi in Metastatic Melanoma
The purpose of this study is to investigate the side effects and safety, and effectiveness of combining dabrafenib and trametinib with radiotherapy.
- Trial name
- CombiRT (NCT02392871)
- Testing
- Palliative radiotherapy, Dabrafenib and trametinib (combination)
- Where
- 3 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05096663
- Testing
- Cobalamin, Dexamethasone, Docetaxel
- Where
- 350 sites in United States
- Volunteers
- 82 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Melanoma, Stage IIIA Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02203604
- Testing
- aldesleukin, ipilimumab, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- CINJRegulatory
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery.
- Conditions
- Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Trial name
- NCT04197687
- Testing
- Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Sargramostim
- Where
- 30 sites in United States
- Volunteers
- 480 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer, Colorectal Cancer
Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight
RATIONALE: Exercise and dietary counseling may improve physical activity, nutrition, and quality of life in older long-term cancer survivors who are overweight.
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT00303875
- Testing
- behavioral dietary and exercise intervention
- Where
- 2 sites in United States
- Volunteers
- 641 people
- Sponsor
- Duke University